Regenxbio: Remains A "Buy Rating" Despite BLA Review Delay Of RGX-121 For Hunter Syndrome

Regenxbio's gene therapy RGX-121 for Hunter syndrome has seen its FDA review extended to February 8, 2026, despite strong 12-month surrogate endpoint data. Concurrently, the company's late-stage Sura-vec trials for Wet-AMD, in partnership with AbbVie, are progressing as planned towards 2026 topline results. Recent strategic partnerships and royalty deals have significantly strengthened Regenxbio's financial position, extending its cash runway into early 2027, which underpins a positive outlook for its pipeline and operational stability.

Analysis

Regenxbio faces a significant regulatory timeline extension for its Hunter syndrome gene therapy, RGX-121, with the new FDA review date now set for February 8, 2026. The impact of this delay is partially mitigated by strong 12-month surrogate endpoint data, which continues to support the therapy's underlying clinical potential. Concurrently, the company's late-stage pipeline remains a key value driver, with the Sura-vec trials for Wet-AMD, conducted in partnership with AbbVie, remaining on schedule to deliver topline results in 2026. From a financial standpoint, Regenxbio has solidified its position through recent partnerships and royalty agreements, securing a cash runway that extends into early 2027. This financial stability is critical, as it allows the company to fund ongoing R&D expenses and absorb the costs of the extended RGX-121 review without immediate financing pressures.

Key Decisions for Investors

• Investors should adjust valuation models to account for the delayed RGX-121 approval timeline, pushing potential revenue contributions out to 2026 or later.
• Monitor the progress of the Sura-vec program, as its 2026 topline data readout in partnership with AbbVie now represents the next major potential value inflection point for the company.
• The secured cash runway to early 2027 reduces near-term financing risk, suggesting the company is well-capitalized to navigate the current R&D and regulatory cycle without needing to raise dilutive capital.